<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260503</url>
  </required_header>
  <id_info>
    <org_study_id>4-2019-0306</org_study_id>
    <nct_id>NCT04260503</nct_id>
  </id_info>
  <brief_title>Gut Microbiome in Biliary Atresia</brief_title>
  <official_title>Analysis of Gut Microbiome and Liver Imaging Including Elasticity in Biliary Atresia Patients With Cholangitis for the Prediction of Disease Activity and Improvement of Outcome Using Fecal Microbiota Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator will investigate the gut-microbiome and liver elasticity of the Biliary&#xD;
      Atresia (BA)-patients before and after Kasai operation. The data will be analyzed according&#xD;
      to their clinical outcomes including cholangitis to find out diagnostic makers, significantly&#xD;
      associated with the BA-phenotypes. The decision-making tree for the BA will be updated with&#xD;
      our data, which will strength the prognosis and prediction. The establishment of gut-liver&#xD;
      axis, featured by cholangitis and gut-microbiome will open new pathway to treat the BA using&#xD;
      fecal microbiota transplantation.&#xD;
&#xD;
        1. Analysis of gut-microbiome: The investigator will investigate the alteration of&#xD;
           gut-microbiome by restoration of bile flow at diagnosis, before and after Kasai&#xD;
           procedure. In case of cholangitis after Kasai operation, signature gut-microbiome will&#xD;
           be analyzed, which will lead to prevention of BA-patients from cholangitis via the&#xD;
           bacteria transplantation.&#xD;
&#xD;
        2. Analysis of elastography: In order to improve non-invasive diagnosis, The investigator&#xD;
           will investigate the alteration of liver elasticity and hepatic blood flow before and&#xD;
           after Kasai procedure as well as upon cholangitis and choledochal cyst. Those data will&#xD;
           be analyzed in parallel with serum biochemical markers to be associated with&#xD;
           pathophysiological events e.g., cholestasis, cholangitis and fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Anticipated">May 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>The changes of gut-microbiome according to the disease.</measure>
    <time_frame>1year</time_frame>
    <description>Using shotgun metagenomic analysis, we will analyze the alteration of gut-microbiota according to the disease phenotypes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of gut microbiome according to the clinical outcomes of biliary atresia.</measure>
    <time_frame>1year</time_frame>
    <description>The investigator will compare gut-microbiome according to the disease prognosis measured by ultrasound elastography and laboratory tests.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Biliary Atresia</condition>
  <arm_group>
    <arm_group_label>Biliary Atresia</arm_group_label>
    <description>Disease group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Choledochal cyst</arm_group_label>
    <description>Disease control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neonatal hepatitis</arm_group_label>
    <description>Disease control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy baby</arm_group_label>
    <description>Healthy control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Monitoring of the gut-microbiome and ultrasound elasticity.</intervention_name>
    <description>The investigator will investigate the alteration of gut-microbiome and liver stiffness by restoration of bile flow by operation.</description>
    <arm_group_label>Biliary Atresia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Monitoring of the gut-microbiome</intervention_name>
    <description>The investigator will investigate the alteration of gut-microbiome before and after operation.</description>
    <arm_group_label>Choledochal cyst</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Monitoring of the gut-microbiome</intervention_name>
    <description>The investigator will investigate the alteration of gut-microbiome along with the disease progress.</description>
    <arm_group_label>Neonatal hepatitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Monitoring of the gut-microbiome.</intervention_name>
    <description>The investigator will investigate the alteration of gut-microbiome according to the normal development.</description>
    <arm_group_label>Healthy baby</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. Biliary atresia Patients, diagnosed with the BA and scheduled for Kasai operation at&#xD;
             Severance children's hospital during study period&#xD;
&#xD;
          2. Choledochal cyst Patients, diagnosed with choledochal cyst and scheduled for total&#xD;
             cyst removal at Severance children's hospital during study period&#xD;
&#xD;
          3. Neonatal hepatitis Patients, diagnosed with the neonatal hepatitis during study period&#xD;
             at Severance chilren's hospital&#xD;
&#xD;
          4. Healthy control Healthy neonates without chronic diseases when they visit Severance&#xD;
             chilren's hospital for vaccination&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Biliary atresia (Disease)&#xD;
&#xD;
             Inclusion Criteria:&#xD;
&#xD;
               -  0-4 months old&#xD;
&#xD;
               -  Patients, diagnosed with the BA and scheduled for Kasai operation during our&#xD;
                  study period&#xD;
&#xD;
               -  Patients whose parents or guardian understand our research aims, and comply to&#xD;
                  participate in our researches&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
               -  Patients, whose diagnosis of BA was not definite.&#xD;
&#xD;
               -  Patients, scheduled for Kasai operation after 4 months old&#xD;
&#xD;
          2. Choledochal cyst (Disease control)&#xD;
&#xD;
             Inclusion Criteria:&#xD;
&#xD;
               -  0-7 years old&#xD;
&#xD;
               -  Patients, diagnosed with choledochal cyst and scheduled for total cyst removal&#xD;
                  during our study period&#xD;
&#xD;
               -  Patients whose parents or guardian understand our research aims, and comply to&#xD;
                  participate in our researches&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
               -  Patients, whose diagnosis of choledochal cysts was not definite.&#xD;
&#xD;
               -  Patients with choledochal cyst, but greater than 7 years old&#xD;
&#xD;
          3. Neonatal hepatitis (Disease control)&#xD;
&#xD;
             Inclusion Criteria:&#xD;
&#xD;
               -  0-4 months old&#xD;
&#xD;
               -  Patients, diagnosed with the neonatal hepatitis during our study period&#xD;
&#xD;
               -  Patients whose parents or guardian understand our research aims, and comply to&#xD;
                  participate in our researches&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
               -  Patients with hepatobiliary infection&#xD;
&#xD;
               -  Patients, required to use antibiotics to treat the infection&#xD;
&#xD;
               -  Patients with hepatobiliary inflammation, caused by abnormal intra- or&#xD;
                  extra-hepatic structure&#xD;
&#xD;
          4. Healthy control&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  0-4 months old&#xD;
&#xD;
          -  Healthy neonates without chronic diseases when they visit for vaccination&#xD;
&#xD;
          -  Healthy neonates whose parents or guardian understand our research aims, and comply to&#xD;
             participate in our researches&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hepatobiliary infection&#xD;
&#xD;
          -  Patients, required to use antibiotics to treat the infection&#xD;
&#xD;
          -  Neonates with less than 37 weeks (i.e., preterm) or hospitalized in neonatal intensive&#xD;
             care unit&#xD;
&#xD;
          -  Patients, diagnosed with congenital malformation, syndrome and chronic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hong Koh, Ph.D</last_name>
    <phone>82-2-2228-2050</phone>
    <email>khong@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pediatric Gastroenterology, Hepatology and Nutrition, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Koh, Ph.D</last_name>
      <email>khong@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biliary atresia</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Cholangitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Atresia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

